90561-83-4

Usage

Uses

Used in Pharmaceutical Development:
3-[(4-bromophenyl)amino]propanoic acid is used as a pharmaceutical candidate for its anti-inflammatory and analgesic properties, making it suitable for the development of treatments targeting conditions that involve inflammation and pain.
Used in Chemical Synthesis:
In the field of organic chemistry, 3-[(4-bromophenyl)amino]propanoic acid is used as a building block for synthesizing other organic compounds, leveraging its unique structure and reactivity to create a variety of chemical products.
Used in Medicinal Chemistry Research:
3-[(4-bromophenyl)amino]propanoic acid is utilized as a research tool in medicinal chemistry to explore its potential interactions with biological targets and to understand its mechanism of action, which can inform the design of new drugs with improved efficacy and safety profiles.
Used in Drug Delivery Systems:
Although not explicitly mentioned in the provided materials, given BAPA's potential pharmaceutical applications, it could also be employed in drug delivery systems to enhance the bioavailability and targeted delivery of therapeutic agents, improving their overall effectiveness and reducing side effects.

Upstream product

• 57-57-8 β-Propiolactone 
• 106-40-1 4-bromo-aniline 
• 79-10-7 acrylic acid 

Downstream Products

• 178425-94-0 1-(4-bromophenyl)-3-ethoxycarbonyl-2-methyl-1,4,5,6-tetrahydro-4(1H)-pyridone 
• 76228-06-3 6-bromo-2,3-dihydro-4(1H)-quinolinone 

Relevant academic research and scientific papers

Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks

Cathepsin L is a cysteine protease that is upregulated in a variety of malignant tumors and plays a significant role in cancer cell invasion and migration. It is an attractive target for the development of small-molecule inhibitors, which may prove beneficial as treatment agents to limit or arrest cancer metastasis. We have previously identified a structurally diverse series of thiosemicarbazone-based inhibitors that incorporate the benzophenone and thiochromanone molecular scaffolds. Herein we report an important extension of this work designed to explore fused aryl-alkyl ring molecular systems that feature nitrogen atom incorporation (dihydroquinoline-based) and carbon atom exclusivity (tetrahydronaphthalene-based). In addition, analogues that contain oxygen (chromanone-based), sulfur (thiochroman-based), sulfoxide, and sulfone functionalization have been prepared in order to further investigate the structure-activity relationship aspects associated with these compounds and their ability to inhibit cathepsins L and B. From this small-library of 30 compounds, five were found to be strongly inhibitory (IC50 50 = 164 nM. All of the compounds evaluated were inactive (IC50 >10,000 nM) as inhibitors of cathepsin B, thus establishing a high degree (>20-fold) of selectivity (cathepsin L vs. cathepsin B) for the most active cathepsin L inhibitors in this series.

BENZOTHIAZOLE COMPOUNDS

The present invention relates to benzothiazole compounds that mimic the activity of BH3 only proteins and are capable of binding to and neutralizing pro survival Bcl 2 proteins. The invention also relates to the use of such compounds in the regulation of cell death or cell survival and the treatment and/or prophylaxis of diseases or conditions associated with the deregulation of cell death or cell survival.